1. Baseline characteristics of study population
Brilakis ES et al. Am J Cardiol 2008;102:552-8

2. Biomarkers at baseline and at four months from study enrollment in different treatment groups
Brilakis ES et al. Am J Cardiol 2008;102:552-8

3. Outcomes in patients with and without previous coronary artery bypass grafting
Brilakis ES et al. Am J Cardiol 2008;102:552-8

4. Outcomes with intensive versus moderate statin therapy in patients with and without previous coronary artery bypass grafting in the PROVE IT-TIMI 22 and A to Z trials
Brilakis ES et al. Am J Cardiol 2008;102:552-8

5. Kaplan-Meier estimate of the incidence of the PROVE IT-TIMI 22 primary end point
Kaplan-Meier estimate of the incidence of the PROVE IT-TIMI 22 primary end point (death/MI, revascularization 30 days from enrollment, unstable angina, and stroke) and the A to Z primary end point (cardiovascular death/MI/stroke/readmission for ACS) in patients with previous CABG and moderate (green line) or intensive (blue line) statin therapy and those without previous CABG and moderate (orange line) or intensive (purple line) statin therapy.
Brilakis ES et al. Am J Cardiol 2008;102:552-8